Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]

Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]

COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a fe...

Full description

Bibliographic Details
Main Authors: Wern Hann Ng, Xiang Liu, Suresh Mahalingam
Format: Article
Language:English
Published: F1000 Research Ltd 2020-08-01
Series:F1000Research
Online Access:https://f1000research.com/articles/9-991/v1
id doaj-1ec9593fb7b54ba68d4f70a28e79c328
record_format Article
spelling doaj-1ec9593fb7b54ba68d4f70a28e79c3282020-11-25T03:51:32ZengF1000 Research LtdF1000Research2046-14022020-08-01910.12688/f1000research.25998.128692Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]Wern Hann Ng0Xiang Liu1Suresh Mahalingam2Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, AustraliaEmerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, AustraliaEmerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, AustraliaCOVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.https://f1000research.com/articles/9-991/v1
collection DOAJ
language English
format Article
sources DOAJ
author Wern Hann Ng
Xiang Liu
Suresh Mahalingam
spellingShingle Wern Hann Ng
Xiang Liu
Suresh Mahalingam
Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]
F1000Research
author_facet Wern Hann Ng
Xiang Liu
Suresh Mahalingam
author_sort Wern Hann Ng
title Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]
title_short Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]
title_full Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]
title_fullStr Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]
title_full_unstemmed Development of vaccines for SARS-CoV-2 [version 1; peer review: 2 approved]
title_sort development of vaccines for sars-cov-2 [version 1; peer review: 2 approved]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2020-08-01
description COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.
url https://f1000research.com/articles/9-991/v1
work_keys_str_mv AT wernhannng developmentofvaccinesforsarscov2version1peerreview2approved
AT xiangliu developmentofvaccinesforsarscov2version1peerreview2approved
AT sureshmahalingam developmentofvaccinesforsarscov2version1peerreview2approved
_version_ 1724487059832307712

Similar Items